Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Delfin Midstream Extends Letter of Award with Samsung Heavy Industries and Executes Purchase Order with Siemens Energy
-
From Combat to Crisis Response: ParaZero's DropAir Achieves Major 2025 Milestones in Precision Airdrops Proven in Recent Conflicts
-
From Combat to Crisis Response: ParaZero's DropAir Achieves Major 2025 Milestones in Precision Airdrops Proven in Recent Conflicts
-
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
-
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
-
Kyivstar Launches 5G Pilot Program in Lviv
-
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares
-
Invitation to HMS Networks’ fourth quarter conference call 2025
-
Kaldalón hf.: Routine Announcement Regarding Share Buybacks Pursuant to Buyback Program
-
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
-
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
-
Pet Valu Appoints Carmen Fortino and Matt Reindel to Board of Directors
-
GoGuardian Launches Hall Pass for Safer Hallways, More Classroom Learning
-
Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call
-
NexGold Provides Summary of 2025 Activities and Key Priorities for 2026
-
Canada’s Biggest Popcorn Celebration: Cineplex Expands National Popcorn Day to Four Days
-
P10 Announces Upcoming Name Change
-
KEY Investment Partners Acquires BellRock Brands’ Portfolio, Home of Mary’s Medicinals, Dixie and Other Top Names
-
RAD Increases Ownership in Radiopharm Ventures to 87.5%
-
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
-
Lyra Therapeutics Provides Corporate Update
-
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
-
Stallion Uranium Refines Coyote Target with Highly Conductive Anomalies from Ground EM Survey, Mobilizes Stone Island VTEM Survey
-
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
-
First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025
-
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
-
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
-
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
-
Zumiez Inc. Reports Holiday 2025 Sales Results
-
Noodles & Company Announces Preliminary Revenue Results for the Fourth Quarter of 2025
-
Emerita Resources Provides Corporate Update
-
Skye Provides 2026 Corporate Outlook
-
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
-
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
-
Highwoods Announces Investment Activity
-
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
-
Sable Announces Director Change
-
Coppernico Defines 155 m of Continuous Copper Mineralization Averaging 0.54% at Sombrero’s Nioc Target
-
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
-
K Wave Media Leads Investment in “Once We Were Us,” Now the #1 Film at the Korean Box Office
-
Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana Validator
-
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
-
Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
-
Surge Copper Appoints Jennifer Anthony as Vice President, Environment and Regulatory Affairs
-
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
-
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
-
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
-
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
-
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
